Compare GPMT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | BDTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.9M | 116.8M |
| IPO Year | N/A | 2020 |
| Metric | GPMT | BDTX |
|---|---|---|
| Price | $1.40 | $2.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.00 | ★ $10.20 |
| AVG Volume (30 Days) | 140.1K | ★ 571.5K |
| Earning Date | 05-05-2026 | 03-16-2026 |
| Dividend Yield | ★ 13.61% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | N/A |
| Revenue This Year | $422.75 | N/A |
| Revenue Next Year | $34.54 | N/A |
| P/E Ratio | ★ N/A | $5.46 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.41 | $1.20 |
| 52 Week High | $3.12 | $4.94 |
| Indicator | GPMT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 23.64 | 39.11 |
| Support Level | N/A | $1.93 |
| Resistance Level | $1.83 | $2.30 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 4.35 | 1.82 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.